41 – 50 of 56
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2001
-
Mark
Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146
(
- Contribution to journal › Article
-
Mark
Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients
(
- Contribution to journal › Article
-
Mark
Measurement of circulating forms of prostate-specific antigen in whole blood immediately after venipuncture: implications for point-of-care testing
(
- Contribution to journal › Article
-
Mark
Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml
(
- Contribution to journal › Article
- 2000
-
Mark
Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections
(
- Contribution to journal › Article
- 1999
-
Mark
Time-resolved fluorescence in immunocytochemical detection of prostate-specific antigen in prostatic tissue sections
(
- Contribution to journal › Article
- 1998
-
Mark
Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum
(
- Contribution to journal › Article
- 1997
-
Mark
Immunoreactivity of recombinant human glandular kallikrein using monoclonal antibodies raised against prostate-specific antigen
(
- Contribution to journal › Article
- 1996
-
Mark
Structural investigation of the alpha-1-antichymotrypsin : Prostate-specific antigen complex by comparative model building
(
- Contribution to journal › Article
-
Mark
A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates : The best case scenario
(
- Contribution to journal › Article